Introduction
Materials and methods
Patients
MRI examination
Image analysis
Reference standard
Statistical analysis
Results
Patients and observations
Characteristic | Total | HCC group | Non-HCC group | P -value |
---|---|---|---|---|
Patient (n = 460) | 460 | 302 | 158 | |
Mean age (years) * | 54.24 ± 11.32 | 56.05 ± 9.65 | 50.75 ± 13.31 | 0.061 |
Sex | 0.000 | |||
Male | 347 (75.4%) | 257 (85.1%) | 90 (57.0%) | |
Female | 113 (24.6%) | 45 (14.9%) | 68 (43.0%) | |
BMI | 23.6 (21.3–25.4) | 23.3 (20.9–24.4) | 23.7 (21.8–26.0) | 0.034 |
Cirrhosis | 0.000 | |||
Presence | 280 (60.9%) | 191(63.2%) | 89 (56.3%) | |
Absence | 180 (39.1%) | 111 (36.8%) | 69 (43.7%) | |
Cause of liver disease | 0.213 | |||
Hepatitis B virus | 368 (78.0%) | 253 (81.6%) | 115 (71.0%) | |
Hepatitis C virus | 62 (13.1%) | 37 (11.9%) | 25 (15.4%) | |
Alcohol | 29 (6.1%) | 11 (3.5%) | 18 (11.1%) | |
NASH | 13 (2.8%) | 9 (2.9%) | 4 (2.5%) | |
Child–Pugh Class | 0.000 | |||
Class A | 386 (83.9%) | 247 (81.8%) | 139 (88.0%) | |
Class B | 60 (13.0%) | 42 (13.9%) | 18 (11.4%) | |
Class C | 14 (3.0%) | 13 (4.3%) | 1 (0.6%) | |
Hepatic function index** | ||||
AST | 20.4 (29–50.7) | 29.3 (20.9–52) | 28.3 (18.5–40.1) | 0.188 |
ALT | 29.6 (21.9–47.9) | 30.3 (23-48.6) | 28.1 (20.6–46.8) | 0.044 |
TBIL (µmol/L) | 13.6 (9.9–20.2) | 14.7 (11.1–20.5) | 12.1 (8.8–17.5) | 0.000 |
PT | 12.3 (11.6–13.5) | 12.3 (11.7–13.5) | 12.2 (11.4–13.6) | 0.161 |
PLT | 143.7 (95.0–194.5) | 140.0(91.0–183.0) | 152.5 (111.8-218.7) | 0.007 |
AFP** | 5.83(2.7–43.1) | 13.1(3.3–143.8) | 3.1(1.9–5.98) | 0.000 |
Lesions(n = 473) | 473 | 311 | 162 | |
No. of nodules | 0.317 | |||
1 | 447 (94.5%) | 293(94.2%) | 154 (95.1%) | |
2 | 13 (6.6%) | 9 (2.9%) | 4 (2.5%) | |
Mean size (cm) | 2.91 ± 2.33 | 3.34 ± 1.75 | 2.08 ± 1.75 | 0.000 |
Degree of differentiation of HCC | ||||
Well differentiated | 54 (17.4%) | |||
Moderately differentiated | 161 (51.8%) | |||
Low-differentiated | 96 (30.9%) | |||
Standard reference of diagnosis | 0.000 | |||
Pathologic diagnosis | 355 (75.1%) | 311 (100%) | 44 (27.2%) | |
Typical imaging features with size stability | 118 (24.9%) | 0 (0%) | 118 (76.6%) |
Frequency of major and ancillary features
LI-RADS features | HCCs(n = 311) | Non-HCC nodules(n = 162) | P value | LR-3 lesions(n = 153) | LR-4 lesions(n = 129) | LR-5 lesions(n = 191) | P value** |
---|---|---|---|---|---|---|---|
Major HCC features | |||||||
Diameter: <10 mm | 4.2(13/311) | 25.3(41/162) | 0.000 | 31.4(48/153) | 3.9(5/129) | 0.5(1/191) | 0.000 |
Diameter: 10–19 mm | 25.1(78/311) | 42.0(68/162) | 0.000 | 60.8(93/153) | 17.8(23/129) | 15.7(30/191) | 0.000 |
Diameter:≥20 mm | 70.7(220/311) | 32.7(53/162) | 0.000 | 7.8(12/153) | 78.3(101/129) | 83.8(160/191) | 0.000 |
Non-rim APHE | 79.7(248/311) | 55.6(90/162) | 0.000 | 52.3(80/153 | 53.5(69/129) | 99.0(189/191) | 0.000 |
Non-peripheral washout | 59.8(186/311) | 10.5(17/162) | 0.000 | 7.2(11/153) | 41.1(53/129) | 72.8(139/191) | 0.000 |
Enhancing capsule | 56.9(177/311) | 11.1(18/162) | 0.000 | 1.3(2/153) | 41.1(53/129) | 73.3(140/191) | 0.000 |
Ancillary features Favoring malignancy in general | |||||||
Mild-moderate T2 hyperintensity | 81.0(252/311) | 50.0(81/162) | 0.000 | 52.9(81/153) | 72.9(94/129) | 82.7(158/191) | 0.000 |
Fat sparing in solid mass | 9.0(28/311) | 9.9(16/162) | 0.742 | 7.8(12/153) | 12.4(16/129) | 8.4(16/191) | 0.359;0.377;0.931 |
Iron sparing in solid mass | 4.8(15/311) | 0.6(1/162) | 0.015 | 1.3(2/153) | 4.7(6/129) | 4.2(8/191) | 0.220;0.170;0.158 |
Corona enhancement | 10.3(32/311) | 9.9(16/162) | 1.000 | 5.2(8/153) | 15.5(20/129) | 10.5(20/191) | 0.017;0.015;0.145 |
TP hypointensity | 25.4(79/311) | 13.0(21/162) | 0.002 | 16.3(25/153) | 25.6(33/129) | 22.0(42/191) | 0.155;0.151;0.235 |
HBP hypointensity | 25.7(80/311) | 14.8(24/162) | 0.007 | 19.6(30/153) | 25.6(33/129) | 21.5(41/191) | 0.471;0.476;0.730 |
Restricted diffusion | 87.1(271/311) | 58.6(95/162) | 0.000 | 60.1(92/153) | 82.9(107/129) | 88.0(168/191) | 0.000 |
Ancillary features Favoring HCC in particular | |||||||
Nodule-in-nodule appearance | 1.0(3/311) | 0(0/162) | 0.554 | 0(0/153) | 0.8(1/129) | 1.0(2/191) | 0.464;0.299;0.231 |
Mosaic appearance | 11.6(36/311) | 0(0/162) | 0.000 | 0(0/153) | 10.1(13/129) | 12.0(23/191) | 0.000 |
Blood product in mass | 17.7(55/311) | 0(0/162) | 0.000 | 1.3(2/153) | 16.3(21/129) | 16.8(32/191) | 0.000 |
Fat in mass | 30.5(95/311) | 11.1(18/162) | 0.000 | 15.0(23/153) | 20.2(26/129) | 33.5(64/191) | 0.000 |
Non-enhancing capsule | 13.5(42/311) | 3.7(6/162) | 0.001 | 3.9(6/153) | 10.1(13/129) | 15.2(29/191) | 0.003;0.002;0.001 |
Ancillary features Favoring benignity | |||||||
Parallel blood pool | 1.0(3/311) | 9.3(15/162) | 0.000 | 7.2(11/153) | 5.4(7/129) | 0(0/191) | 0.001 |
Undistorted vessels | 3.5(11/311) | 0.6(1/162) | 0.066 | 0.7(1/153) | 3.9(5/129) | 3.1(6/191) | 0.182;0.124;0.165 |
Iron in mass more than liver | 0(0/311) | 0(0/162) | NA | 0(0/153) | 0(0/129) | 0(0/191) | NA |
Marked T2 hyperintensity | 1.0(3/311) | 21.6(35/162) | 0.000 | 16.3(25/153) | 8.5(11/129) | 1.0(2/191) | 0.000 |
HBP isointensity | 1.6(5/311) | 16.7(27/162) | 0.000 | 15.0(23/153) | 5.4(7/129) | 1.0(2/191) | 0.000 |
Logistic regression model for screening features and model self-validation
Variables | Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|
Beta | OR (95%CI) | P | aBeta | aOR (95%CI) | aP | |
Nodule-in-nodule architecture | -1.40 | 0.25 (0.10–0.59) | 0.002 | -1.34 | 0.26 (0.06–1.13) | 0.073 |
Nonenhancing “capsule” | -13.92 | 0.00 (0.00 - Inf) | 0.978 | |||
Mosaic architecture | -17.04 | 0.00 (0.00 - Inf) | 0.979 | |||
Blood products in mass | -17.11 | 0.00 (0.00 - Inf) | 0.974 | |||
Fat in mass | 0.83 | 2.29 (1.35–3.86) | 0.002 | |||
Subthreshold growth | 14.22 | 1505228.15 (0.00 - Inf) | 0.979 | |||
Restricted diffusion | 1.59 | 4.92 (3.11–7.78) | < 0.001 | 1.81 | 6.11 (2.56–14.61) | < 0.001 |
Mild–moderate T2 hyperintensity | -0.05 | 0.96 (0.51–1.80) | 0.888 | 1.57 | 4.79 (1.62–14.14) | 0.005 |
Coronal enhancement | 1.45 | 4.27 (2.81–6.49) | < 0.001 | |||
Fat sparing | 0.10 | 1.11 (0.58–2.11) | 0.756 | |||
Iron sparing | -2.10 | 0.12 (0.02–0.94) | 0.043 | -2.03 | 0.13 (0.01–1.18) | 0.070 |
Transitional-phase hypointensity | -1.26 | 0.28 (0.16–0.49) | < 0.001 | -0.95 | 0.39 (0.16–0.92) | 0.032 |
Hepatobiliary-phase hypointensity | 0.69 | 1.99 (1.20–3.29) | 0.007 | |||
Parallels blood pool enhancement | 2.35 | 10.48 (2.99–36.75) | < 0.001 | |||
Undistorted vessels | -1.78 | 0.17 (0.02–1.32) | 0.090 | -1.74 | 0.18 (0.02–1.70) | 0.133 |
Marked T2 hyperintensity | 3.34 | 28.29 (8.55–93.66) | < 0.001 | 2.96 | 19.22 (3.38–109.24) | < 0.001 |
HBP isointensity | 2.50 | 12.24 (4.61–32.47) | < 0.001 | 1.72 | 5.57 (1.44–21.56) | 0.013 |
Variables | Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|
Beta | OR (95%CI) | P | aBeta | aOR (95%CI) | aP | |
Nodule-in-nodule architecture | -16.78 | 0.00 (0.00 - Inf) | 0.980 | -16.81 | 0.00 (0.00 - Inf) | 0.994 |
Nonenhancing “capsule” | -14.69 | 0.00 (0.00 - Inf) | 0.987 | |||
Mosaic architecture | -1.53 | 0.22 (0.07–0.67) | 0.038 | -2.34 | 0.10 (0.01–0.69) | 0.02 |
Blood products in mass | -17.87 | 0.00 (0.00 - Inf) | 0.983 | |||
Fat in mass | -1.53 | 0.22 (0.07–0.67) | 0.008 | -2.42 | 0.09 (0.01–0.86) | 0.036 |
Subthreshold growth | 14.46 | 1903499.57 (0.00 - Inf) | 0.987 | |||
Restricted diffusion | 1.51 | 4.52 (2.52–8.10) | < 0.001 | 1.89 | 6.64 (2.70–16.30) | < 0.001 |
Mild–moderate T2 hyperintensity | 1.44 | 4.23 (2.50–7.17) | < 0.001 | 0.18 | 1.19 (0.49–2.88) | 0.695 |
Coronal enhancement | -0.61 | 0.54 (0.24–1.21) | 0.135 | |||
Fat sparing | 0.19 | 1.21 (0.55–2.67) | 0.631 | |||
Iron sparing | -2.11 | 0.12 (0.01–1.00) | 0.050 | -2.04 | 0.13 (0.01–1.36) | 0.089 |
Transitional-phase hypointensity | -1.04 | 0.35 (0.19–0.65) | < 0.001 | -0.88 | 0.42 (0.06–3.10) | 0.393 |
Hepatobiliary-phase hypointensity | -0.94 | 0.39 (0.22–0.70) | 0.001 | 0.00 | 1.00 (0.14–7.13) | 1.000 |
Parallels blood pool enhancement | 1.58 | 4.85 (1.37–17.15) | 0.014 | 0.57 | 1.76 (0.31–9.97) | 0.521 |
Undistorted vessels | -1.75 | 0.17 (0.02–1.50) | 0.111 | |||
Marked T2 hyperintensity | 2.96 | 19.37 (4.55–82.38) | < 0.001 | 3.42 | 30.44 (4.52–205.11) | < 0.001 |
HBP isointensity | 2.26 | 9.59 (2.84–32.42) | < 0.001 | 1.73 | 5.62 (1.39–22.73) | 0.016 |
Diagnostic performance of criteria using screened ancillary features
Variable | level | Overall | HCC group (LR-3/4 n = 133) | Non-HCC group (LR-3/4 n = 149) | Sensitivity (%) | Specificity (%) | Kappa test | P |
---|---|---|---|---|---|---|---|---|
(a) Based on ancillary features screened from all lesions | 0.695 | 0.000 | ||||||
Degrade | 5.7(16/282) | 0.0 (0/133) | 10.7(16/149) | 84.96 (113/133) | 89.26 (133/149) | |||
Retain | 32.6(92/282) | 15.0(20/133) | 48.3(72/149) | |||||
Upgrade | 61.7(174/282) | 85.0(113/133) | 40.9(61/149) | |||||
(b) Based on ancillary features screened from LR-3/LR-4 lesions | ||||||||
Degrade | 5.3(15/282) | 0.8(1/133) | 9.4(14/149) | 85.71 (114/133) | 90.60 (135/149) | |||
Retain | 29.4(83/282) | 13.5(18/133) | 43.6(65/149) | |||||
Upgrade | 65.2(184/282) | 85.6(114/133) | 47.0(70/149) |